Role of mmps in metastatic dissemination: Implications for therapeutic advances

Current Pharmaceutical Biotechnology

Volumn 12, Issue 11, 2011, Pages 1937-1947

  Raffo, D ^a   Pontiggia, O ^a   Simian, M ^a  

^a Instituto de Oncologia Angel H Roffo   (Argentina)

Author keywords

Cancer; Clinical trials; Matrix metalloproteinases; Mmp inhibitors; Therapy

Indexed keywords

AE 941; BATIMASTAT; COLLAGENASE 3; GELATINASE A; GELATINASE B; ILOMASTAT; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE 26; NEUTROPHIL COLLAGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRINOMASTAT; REBIMASTAT; STAT3 PROTEIN; STROMELYSIN; STROMELYSIN 2; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN RECEPTOR 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BASEMENT MEMBRANE; BINDING SITE; BREAST ADENOCARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER LOCALIZATION; CARCINOGENESIS; CATALYSIS; CELL STRAIN CACO 2; CELL STRAIN MCF 7; COLON ADENOCARCINOMA; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; EXTRAVASATION; FIBROSARCOMA; HUMAN; KIDNEY CARCINOMA; LUNG CARCINOMA; LUNG METASTASIS; MELANOMA CELL; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROGNOSIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; TARGET ORGAN; TUMOR MICROENVIRONMENT; WOUND HEALING;

EID: 83455259796     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798377085     Document Type: Review

References (117)

1. Puente, X.S.; Lopez-Otin, C. A genomic analysis of rat proteases and protease inhibitors. Genome Res., 2004, 14(4), 609-622.
2. Harper, E.; Bloch, K.J.; Gross, J. The zymogen of tadpole collagenase. Biochemistry, 1971, 10(16), 3035-3041.
3. Overall, C.M. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol. Biotechnol., 2002, 22(1), 51-86.
4. Uria, J.A.; Lopez-Otin, C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res., 2000, 60(17), 4745-4751.
5. Morgunova, E.; Tuuttila, A.; Bergmann, U.; Isupov, M.; Lindqvist, Y.; Schneider, G.; Tryggvason, K. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science, 1999, 284(5420), 1667-1670.
6. Zucker, S.; Pei, D.; Cao, J.; Lopez-Otin, C. Membrane type-matrix metalloproteinases (MT-MMP). Curr. Top. Dev. Biol., 2003, 54, 1-74.
7. Talhouk, R.S.; Chin, J.R.; Unemori, E.N.; Werb, Z.; Bissell, M.J. Proteinases of the mammary gland: developmental regulation in vivo and vectorial secretion in culture. Development, 1991, 112(2), 439-449.
8. Talhouk, R.S.; Bissell, M.J.; Werb, Z. Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J. Cell Biol., 1992, 118(5), 1271-1282.
9. Clark, I.M.; Swingler, T.E.; Sampieri, C.L.; Edwards, D.R. The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol., 2008, 40(6-7), 1362-1378.
10. Angel, P.; Baumann, I.; Stein, B.; Delius, H.; Rahmsdorf, H.J.; Herrlich, P. 12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5'-flanking region. Mol. Cell Biol., 1987, 7(6), 2256-2266.
11. Sternlicht, M.D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol., 2001, 17, 463-516.
12. Yan, C.; Boyd, D.D. Regulation of matrix metalloproteinase gene expression. J. Cell Physiol., 2007, 211(1), 19-26.
13. Song, Y.; Qian, L.; Song, S.; Chen, L.; Zhang, Y.; Yuan, G.; Zhang, H.; Xia, Q.; Hu, M.; Yu, M.; Shi, M.; Jiang, Z.; Guo, N. Fra-1 and Stat3 synergistically regulate activation of human MMP-9 gene. Mol. Immunol., 2008, 45(1), 137-143.
14. Fahmi, H.; Pelletier, J.P.; Di Battista, J.A.; Cheung, H.S.; Fernandes, J.C.; Martel-Pelletier, J. Peroxisome proliferatoractivated receptor gamma activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1. Osteoarthritis. Cartilage., 2002, 10(2), 100-108.
15. Francois, M.; Richette, P.; Tsagris, L.; Raymondjean, M.; Fulchignoni-Lataud, M.C.; Forest, C.; Savouret, J.F.; Corvol, M.T. Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element. J. Biol. Chem., 2004, 279(27), 28411-28418.
16. Crawford, H.C.; Fingleton, B.M.; Rudolph-Owen, L.A.; Goss, K.J.; Rubinfeld, B.; Polakis, P.; Matrisian, L.M. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene, 1999, 18(18), 2883-2891.
17. Takahashi, M.; Tsunoda, T.; Seiki, M.; Nakamura, Y.; Furukawa, Y. Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene, 2002, 21(38), 5861-5867.
18. Bian, J.; Sun, Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol. Cell Biol., 1997, 17(11), 6330-6338.
19. Sun, Y.; Wenger, L.; Rutter, J.L.; Brinckerhoff, C.E.; Cheung, H.S. p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression. J. Biol. Chem., 1999, 274(17), 11535-11540.
20. Jimenez, M.J.; Balbin, M.; Lopez, J.M.; Alvarez, J.; Komori, T.; Lopez-Otin, C. Collagenase 3 is a target of Cbfa1, a transcription factor of the runt gene family involved in bone formation. Mol.Cell Biol., 1999, 19(6), 4431-4442.
21. Porte, D.; Tuckermann, J.; Becker, M.; Baumann, B.; Teurich, S.; Higgins, T.; Owen, M.J.; Schorpp-Kistner, M.; Angel, P. Both AP-1 and Cbfa1-like factors are required for the induction of interstitial collagenase by parathyroid hormone. Oncogene, 1999, 18(3), 667-678.
22. Harendza, S.; Lovett, D.H.; Panzer, U.; Lukacs, Z.; Kuhnl, P.; Stahl, R.A. Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J. Biol.Chem., 2003, 278(23), 20490-20499.
23. Price, S.J.; Greaves, D.R.; Watkins, H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J. Biol.Chem., 2001, 276(10), 7549-7558.
24. Ye, S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol., 2000, 19(7), 623-629.
25. Zhang, B.; Ye, S.; Herrmann, S.M.; Eriksson, P.; de, M.M.; Evans, A.; Arveiler, D.; Luc, G.; Cambien, F.; Hamsten, A.; Watkins, H.; Henney, A.M. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation, 1999, 99(14), 1788-1794.
26. Springman, E.B.; Angleton, E.L.; Birkedal-Hansen, H.; Van Wart, H.E. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a cysteine switch mechanism for activation. Proc. Natl. Acad. Sci. USA, 1990, 87(1), 364-368.
27. Thomas, G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol., 2002, 3(10), 753-766.
28. Illman, S.A.; Keski-Oja, J.; Parks, W.C.; Lohi, J. The mouse matrix metalloproteinase, epilysin (MMP-28), is alternatively spliced and processed by a furin-like proprotein convertase. Biochem. J., 2003, 375(Pt 1), 191-197.
29. Strongin, A.Y.; Collier, I.; Bannikov, G.; Marmer, B.L.; Grant, G.A.; Goldberg, G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol.Chem., 1995, 270(10), 5331-5338.
30. Creemers, E.; Cleutjens, J.; Smits, J.; Heymans, S.; Moons, L.; Collen, D.; Daemen, M.; Carmeliet, P. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am. J. Pathol., 2000, 156(6), 1865-1873.
31. Lijnen, H.R.; Silence, J.; Lemmens, G.; Frederix, L.; Collen, D. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system. Thromb. Haemost., 1998, 79(6), 1171-1176.
32. Lund, L.R.; Romer, J.; Bugge, T.H.; Nielsen, B.S.; Frandsen, T.L.; Degen, J.L.; Stephens, R.W.; Dano, K. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J., 1999, 18(17), 4645-4656.
33. Ra, H.J.; Parks, W.C. Control of matrix metalloproteinase catalytic activity. Matrix Biol., 2007, 26(8), 587-596.
34. Lambert, E.; Dasse, E.; Haye, B.; Petitfrere, E. TIMPs as multifacial proteins. Crit. Rev. Oncol. Hematol., 2004, 49(3), 187-198.
35. Gomez, D.E.; Alonso, D.F.; Yoshiji, H.; Thorgeirsson, U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol., 1997, 74(2), 111-122.
36. Wilhelm, S.M.; Collier, I.E.; Marmer, B.L.; Eisen, A.Z.; Grant, G.A.; Goldberg, G.I. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem., 1989, 264(29), 17213-17221.
37. Butler, G.S.; Apte, S.S.; Willenbrock, F.; Murphy, G. Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and Cterminal domains of gelatinases A and B. Regulation by polyanions. J. Biol. Chem., 1999, 274(16), 10846-10851.
38. Bigg, H.F.; Shi, Y.E.; Liu, Y.E.; Steffensen, B.; Overall, C.M. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexinlike domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. J. Biol. Chem., 1997, 272(24), 15496-15500.
39. Howard, E.W.; Banda, M.J. Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. Identification of a stabilization site. J. Biol. Chem., 1991, 266(27), 17972-17977.
40. Ward, R.V.; Hembry, R.M.; Reynolds, J.J.; Murphy, G. The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1. Biochem. J., 1991, 278 (Pt 1), 179-187.
41. Guo, Y.H.; Gao, W.; Li, Q.; Li, P.F.; Yao, P.Y.; Chen, K. Tissue inhibitor of metalloproteinases-4 suppresses vascular smooth muscle cell migration and induces cell apoptosis. Life Sci., 2004, 75(20), 2483-2493.
42. Tummalapalli, C.M.; Heath, B.J.; Tyagi, S.C. Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J. Cell Biochem., 2001, 80(4), 512-521.
43. Jiang, Y.; Wang, M.; Celiker, M.Y.; Liu, Y.E.; Sang, Q.X.; Goldberg, I.D.; Shi, Y.E. Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res., 2001, 61(6), 2365-2370.
44. Yoshiji, H.; Harris, S.R.; Raso, E.; Gomez, D.E.; Lindsay, C.K.; Shibuya, M.; Sinha, C.C.; Thorgeirsson, U.P. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int. J. Cancer, 1998, 75(1), 81-87.
45. Jeffery, N.; McLean, M.H.; El-Omar, E.M.; Murray, G.I. The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers. Histopathology, 2009, 54(7), 820-828.
46. Kuvaja, P.; Talvensaari-Mattila, A.; Turpeenniemi-Hujanen, T. High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma. Int. J. Cancer, 2008, 123(4), 846-851.
47. Kaplan, R.N.; Riba, R.D.; Zacharoulis, S.; Bramley, A.H.; Vincent, L.; Costa, C.; MacDonald, D.D.; Jin, D.K.; Shido, K.; Kerns, S.A.; Zhu, Z.; Hicklin, D.; Wu, Y.; Port, J.L.; Altorki, N.; Port, E.R.; Ruggero, D.; Shmelkov, S.V.; Jensen, K.K.; Rafii, S.; Lyden, D. VEGFR1-positive haematopoietic bone marrow progenitors initiatethe pre-metastatic niche. Nature, 2005, 438(7069), 820-827.
48. Hiratsuka, S.; Watanabe, A.; Aburatani, H.; Maru, Y. Tumourmediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol., 2006, 8(12), 1369-1375.
49. Hiratsuka, S.; Nakamura, K.; Iwai, S.; Murakami, M.; Itoh, T.; Kijima, H.; Shipley, J.M.; Senior, R.M.; Shibuya, M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell, 2002, 2(4), 289-300.
50. Huang, Y.; Song, N.; Ding, Y.; Yuan, S.; Li, X.; Cai, H.; Shi, H.; Luo, Y. Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res., 2009, 69(19), 7529-7537.
51. Christofori, G. New signals from the invasive front. Nature, 2006, 441(7092), 444-450.
52. Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer, 2002, 2(6), 442-454.
53. Oft, M.; Peli, J.; Rudaz, C.; Schwarz, H.; Beug, H.; Reichmann, E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev., 1996, 10(19), 2462-2477.
54. Huber, M.A.; Kraut, N.; Beug, H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol., 2005, 17(5), 548-558.
55. Pardal, R.; Clarke, M.F.; Morrison, S.J. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer, 2003, 3(12), 895-902.
56. Polyak, K.; Weinberg, R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer, 2009, 9(4), 265-273.
57. Batlle, E.; Sancho, E.; Franci, C.; Dominguez, D.; Monfar, M.; Baulida, J.; Garcia De, H.A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol., 2000, 2(2), 84-89.
58. Cano, A.; Perez-Moreno, M.A.; Rodrigo, I.; Locascio, A.; Blanco, M.J.; del Barrio, M.G.; Portillo, F.; Nieto, M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol., 2000, 2(2), 76-83.
59. Comijn, J.; Berx, G.; Vermassen, P.; Verschueren, K.; van, G.L.; Bruyneel, E.; Mareel, M.; Huylebroeck, D.; van, R.F. The twohanded E box binding zinc finger protein SIP1 downregulates Ecadherin and induces invasion. Mol. Cell, 2001, 7(6), 1267-1278.
60. Eger, A.; Aigner, K.; Sonderegger, S.; Dampier, B.; Oehler, S.; Schreiber, M.; Berx, G.; Cano, A.; Beug, H.; Foisner, R. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene, 2005, 24(14), 2375-2385.
61. Geiger, T.R.; Peeper, D.S. Metastasis mechanisms. Biochim. Biophys. Acta, 2009, 1796(2), 293-308.
62. Olmeda, D.; Jorda, M.; Peinado, H.; Fabra, A.; Cano, A. Snail silencing effectively suppresses tumour growth and invasiveness. Oncogene, 2007, 26(13), 1862-1874.
63. Yokoyama, K.; Kamata, N.; Fujimoto, R.; Tsutsumi, S.; Tomonari, M.; Taki, M.; Hosokawa, H.; Nagayama, M. Increased invasion and matrix metalloproteinase-2 expression by Snail-induced mesenchymal transition in squamous cell carcinomas. Int. J. Oncol., 2003, 22(4), 891-898.
64. Bolos, V.; Peinado, H.; Perez-Moreno, M.A.; Fraga, M.F.; Esteller, M.; Cano, A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J. Cell Sci., 2003, 116(Pt 3), 499-511.
65. Hajra, K.M.; Chen, D.Y.; Fearon, E.R. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res., 2002, 62(6), 1613-1618.
66. Huang, C.H.; Yang, W.H.; Chang, S.Y.; Tai, S.K.; Tzeng, C.H.; Kao, J.Y.; Wu, K.J.; Yang, M.H. Regulation of membrane-type 4 matrix metalloproteinase by SLUG contributes to hypoxiamediated metastasis. Neoplasia., 2009, 11(12), 1371-1382.
67. Radisky, D.C.; Levy, D.D.; Littlepage, L.E.; Liu, H.; Nelson, C.M.; Fata, J.E.; Leake, D.; Godden, E.L.; Albertson, D.G.; Nieto, M.A.; Werb, Z.; Bissell, M.J. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature, 2005, 436(7047), 123-127.
68. Ossowski, L.; Reich, E. Experimental model for quantitative study of metastasis. Cancer Res., 1980, 40(7), 2300-2309.
69. Kim, J.; Yu, W.; Kovalski, K.; Ossowski, L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell, 1998, 94(3), 353-362.
70. Deryugina, E.I.; Zijlstra, A.; Partridge, J.J.; Kupriyanova, T.A.; Madsen, M.A.; Papagiannakopoulos, T.; Quigley, J.P. Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Cancer Res., 2005, 65(23), 10959-10969.
71. Ota, I.; Li, X.Y.; Hu, Y.; Weiss, S.J. Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proc. Natl. Acad. Sci. USA, 2009, 106(48), 20318-20323.
72. Tien, Y.W.; Lee, P.H.; Hu, R.H.; Hsu, S.M.; Chang, K.J. The role of gelatinase in hepatic metastasis of colorectal cancer. Clin. Cancer Res., 2003, 9(13), 4891-4896.
73. Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer, 2002, 2(8), 563-572.
74. Kataoka, H.; Uchino, H.; Iwamura, T.; Seiki, M.; Nabeshima, K.; Koono, M. Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alpha1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. Am. J. Pathol., 1999, 154(2), 457-468.
75. Sheu, B.C.; Hsu, S.M.; Ho, H.N.; Lien, H.C.; Huang, S.C.; Lin, R.H. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res., 2001, 61(1), 237-242.
76. Jurasz, P.; onso-Escolano, D.; Radomski, M.W. Platelet-cancer interactions: mechanisms and pharmacology of tumour cellinduced platelet aggregation. Br. J. Pharmacol., 2004, 143(7), 819-826.
77. Alonso-Escolano, D.; Strongin, A.Y.; Chung, A.W.; Deryugina, E.I.; Radomski, M.W. Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br. J. Pharmacol., 2004, 141(2), 241-252.
78. Jurasz, P.; Sawicki, G.; Duszyk, M.; Sawicka, J.; Miranda, C.; Mayers, I.; Radomski, M.W. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res., 2001, 61(1), 376-382.
79. Medina, C.; Jurasz, P.; Santos-Martinez, M.J.; Jeong, S.S.; Mitsky, T.; Chen, R.; Radomski, M.W. Platelet aggregation-induced by caco-2 cells: regulation by matrix metalloproteinase-2 and adenosine diphosphate. J. Pharmacol. Exp. Ther., 2006, 317(2), 739-745.
80. Alonso-Escolano, D.; Medina, C.; Cieslik, K.; Radomski, A.; Jurasz, P.; Santos-Martinez, M.J.; Jiffar, T.; Ruvolo, P.; Radomski, M.W. Protein kinase C delta mediates platelet-induced breast cancer cell invasion. J. Pharmacol. Exp. Ther., 2006, 318(1), 373-380.
81. Janowska-Wieczorek, A.; Wysoczynski, M.; Kijowski, J.; Marquez-Curtis, L.; Machalinski, B.; Ratajczak, J.; Ratajczak, M.Z. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int. J. Cancer, 2005, 113(5), 752-760.
82. Al-Mehdi, A.B.; Tozawa, K.; Fisher, A.B.; Shientag, L.; Lee, A.; Muschel, R.J. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat. Med., 2000, 6(1), 100-102.
83. Wylie, S.; MacDonald, I.C.; Varghese, H.J.; Schmidt, E.E.; Morris, V.L.; Groom, A.C.; Chambers, A.F. The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin. Exp. Metastasis, 1999, 17(2), 111-117.
84. Kasaoka, T.; Nishiyama, H.; Okada, M.; Nakajima, M. Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models. Clin. Exp. Metastasis, 2008, 25(7), 827-834.
85. Cockett, M.I.; Murphy, G.; Birch, M.L.; O'Connell, J.P.; Crabbe, T.; Millican, A.T.; Hart, I.R.; Docherty, A.J. Matrix metalloproteinases and metastatic cancer. Biochem. Soc. Symp., 1998, 63, 295-313.
86. Cruz-Munoz, W.; Kim, I.; Khokha, R. TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis. Oncogene, 2006, 25(4), 650-655.
87. Yamamoto, N.; Yang, M.; Jiang, P.; Xu, M.; Tsuchiya, H.; Tomita, K.; Moossa, A.R.; Hoffman, R.M. Determination of clonality of metastasis by cell-specific color-coded fluorescent-protein imaging. Cancer Res., 2003, 63(22), 7785-7790.
88. Fidler, I.J.; Kim, S.J.; Langley, R.R. The role of the organ microenvironment in the biology and therapy of cancer metastasis. J. Cell Biochem., 2007, 101(4), 927-936.
89. Acuff, H.B.; Carter, K.J.; Fingleton, B.; Gorden, D.L.; Matrisian, L.M. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Res., 2006, 66(1), 259-266.
90. Saha, A.; Lee, Y.C.; Zhang, Z.; Chandra, G.; Su, S.B.; Mukherjee, A.B. Lack of an Endogenous Anti-inflammatory Protein in Mice Enhances Colonization of B16F10 Melanoma Cells in the Lungs. J. Biol.Chem., 285(14), 10822-10831.
91. Bartolome, R.A.; Ferreiro, S.; Miquilena-Colina, M.E.; Martinez-Prats, L.; Soto-Montenegro, M.L.; Garcia-Bernal, D.; Vaquero, J.J.; Agami, R.; Delgado, R.; Desco, M.; Sanchez-Mateos, P.; Teixido, J. The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am. J. Pathol., 2009, 174(2), 602-612.
92. Balbin, M.; Fueyo, A.; Tester, A.M.; Pendas, A.M.; Pitiot, A.S.; Astudillo, A.; Overall, C.M.; Shapiro, S.D.; Lopez-Otin, C. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat. Genet., 2003, 35(3), 252-257.
93. McCawley, L.J.; Crawford, H.C.; King, L.E., Jr.; Mudgett, J.; Matrisian, L.M. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res., 2004, 64(19), 6965-6972.
94. McCawley, L.J.; Wright, J.; LaFleur, B.J.; Crawford, H.C.; Matrisian, L.M. Keratinocyte expression of MMP3 enhances differentiation and prevents tumor establishment. Am. J. Pathol., 2008, 173(5), 1528-1539.
95. Houghton, A.M.; Grisolano, J.L.; Baumann, M.L.; Kobayashi, D.K.; Hautamaki, R.D.; Nehring, L.C.; Cornelius, L.A.; Shapiro, S.D. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res., 2006, 66(12), 6149-6155.
96. Savinov, A.Y.; Remacle, A.G.; Golubkov, V.S.; Krajewska, M.; Kennedy, S.; Duffy, M.J.; Rozanov, D.V.; Krajewski, S.; Strongin, A.Y. Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res., 2006, 66(5), 2716-2724.
97. Simian, M.; Molinolo, A.; Lanari, C. Involvement of matrix metalloproteinase activity in hormone-induced mammary tumor regression. Am. J. Pathol., 2006, 168(1), 270-279.
98. Hettiaratchi, A.; Hawkins, N.J.; McKenzie, G.; Ward, R.L.; Hunt, J.E.; Wakefield, D.; Di, G.N. The collagenase-1 (MMP-1) gene promoter polymorphism - 1607/2G is associated with favourable prognosis in patients with colorectal cancer. Br. J. Cancer, 2007, 96(5), 783-792.
99. Scorilas, A.; Karameris, A.; Arnogiannaki, N.; Ardavanis, A.; Bassilopoulos, P.; Trangas, T.; Talieri, M. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br. J. Cancer, 2001, 84(11), 1488-1496.
100. Takeha, S.; Fujiyama, Y.; Bamba, T.; Sorsa, T.; Nagura, H.; Ohtani, H. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn. J. Cancer Res., 1997, 88(1), 72-81.
101. Talvensaari-Mattila, A.; Turpeenniemi-Hujanen, T. Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma. Cancer Lett., 2005, 217(2), 237-242.
102. Andarawewa, K.L.; Boulay, A.; Masson, R.; Mathelin, C.; Stoll, I.; Tomasetto, C.; Chenard, M.P.; Gintz, M.; Bellocq, J.P.; Rio, M.C. Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res., 2003, 63(18), 5844-5849.
103. Pendas, A.M.; Folgueras, A.R.; Llano, E.; Caterina, J.; Frerard, F.; Rodriguez, F.; Astudillo, A.; Noel, A.; Birkedal-Hansen, H.; Lopez-Otin, C. Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol. Cell Biol., 2004, 24(12), 5304-5313.
104. Davies, B.; Brown, P.D.; East, N.; Crimmin, M.J.; Balkwill, F.R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res., 1993, 53(9), 2087-2091.
105. Grobelny, D.; Poncz, L.; Galardy, R.E. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry, 1992, 31(31), 7152-7154.
106. Davidson, S. Is British Biotech's Marimastat a major cancer drug? Nat. Biotechnol., 1996, 14(7), 819-820.
107. Overall, C.M.; Kleifeld, O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer, 2006, 94(7), 941-946.
108. Roy, R.; Yang, J.; Moses, M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol., 2009, 27(31), 5287-5297.
109. Dublanchet, A.C.; Ducrot, P.; Andrianjara, C.; O'Gara, M.; Morales, R.; Compere, D.; Denis, A.; Blais, S.; Cluzeau, P.; Courte, K.; Hamon, J.; Moreau, F.; Prunet, M.L.; Tertre, A. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. Bioorg. Med. Chem. Lett., 2005, 15(16), 3787-3790.
110. Moy, F.J.; Chanda, P.K.; Chen, J.M.; Cosmi, S.; Edris, W.; Levin, J.I.; Powers, R. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor. J. Mol.Biol., 2000, 302(3), 671-689.
111. Wilson, W.R.; Evans, J.; Bell, P.R.; Thompson, M.M. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur. J. Vasc. Endovasc. Surg., 2005, 30(3), 259-262.
112. Ferretti, G.; Fabi, A.; Carlini, P.; Papaldo, P.; Cordiali, F.P.; Di, C.S.; Salesi, N.; Giannarelli, D.; Alimonti, A.; Di, C.B.; D'Agosto, G.; Bordignon, V.; Trento, E.; Cognetti, F. Zoledronic-acidinduced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology, 2005, 69(1), 35-43.
113. Acharya, M.R.; Venitz, J.; Figg, W.D.; Sparreboom, A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist. Updat., 2004, 7(3), 195-208.
114. Gingras, D.; Batist, G.; Beliveau, R. AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert. Rev. Anticancer Ther., 2001, 1(3), 341-347.
115. Batist, G.; Patenaude, F.; Champagne, P.; Croteau, D.; Levinton, C.; Hariton, C.; Escudier, B.; Dupont, E. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann. Oncol., 2002, 13(8), 1259-1263.
116. Lu, C.; Lee, J.J.; Komaki, R.; Herbst, R.S.; Feng, L.; Evans, W.K.; Choy, H.; Desjardins, P.; Esparaz, B.T.; Truong, M.T.; Saxman, S.; Kelaghan, J.; Bleyer, A.; Fisch, M.J. Chemoradiotherapy With or Without AE-941 in Stage III Non-Small Cell Lung Cancer: A Randomized Phase III Trial. J. Natl. Cancer Inst., 2010, 102(12),859-65
117. Fingleton, B. MMPs as therapeutic targets--still a viable option? Semin. Cell Dev. Biol., 2008, 19(1), 61-68.